At the news
? NEUTRALIMPACT 2/10 SC 13G/A filed Nov 5, 2026 at 13:22 ET
FMR LLC (Fidelity) filed an amended Schedule 13G disclosing a 4.2% passive stake in Nurix Therapeutics as of September 30, 2026, down from a prior position. The filing confirms Fidelity remains a significant passive holder but below the 5% threshold, with no intent to influence control.
- FMR LLC reported beneficial ownership of 4,350,596.42 shares of Nurix Therapeutics common stock as of September 30, 2026.
- The stake represents 4.2% of shares outstanding, below the 5% threshold.
- This is an amendment to a prior Schedule 13G filing, indicating a decrease from a previously larger position.
- FMR LLC certifies the shares were acquired and are held in the ordinary course of business with no intent to influence control.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access